October 2013, Santa Clara, California Oral Presentation: High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain
American Chemical Society, Western Regional Meeting 2013
read more
Conferences
3rd International Workshop on Nitric Oxide in Cancer Therapy 2013
May 2013, Kingston, Ontario Abstract: RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results
American Association for Cancer Research (AACR) Annual Meeting 2013
April 2013, Washington, D.C. Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent
15th International Symposium on Anti-Angiogenic Therapy 2013
January 2013, La Jolla, California Abstract: Antivascular activity of RRx-001 in SCCVII and U87 tumors Abstract: RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA) Abstract: Preliminary results from an ongoing phase I trial of...
American Society of Hematology (ASH) 2012
December 2012, Atlanta Georgia Abstract: Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells
American Association for Cancer Research (AACR) Annual Meeting 2012
March 2012, Chicago Illinois Abstract: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors
American Society of Hematology (ASH) 2011
December 2011, San Diego, California Abstract: NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells
International Society for the Study of Xenobiotics (ISSX) 2011
April 2011, Atlanta, Georgia Abstract: Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans
American Association for Cancer Research (AACR) Annual Meeting 2011
April 2011, Orlando, Florida Abstract: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’